ArticleFrontiers in psychiatry2026
Multimodal neuroimaging alterations in schizophrenia model rats and the modulatory effects of risperidone: a pilot study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The hippocampus is considered to be closely associated with the emergence of negative symptoms and cognitive impairments in schizophrenia (SCH). A single imaging modality is insufficient to capture the comprehensive structural, functional, and metabolic alterations in the hippocampus. This study employed multimodal magnetic resonance imaging (MRI) to investigate changes in hippocampal volume, white matter integrity, and metabolite levels in SCH rats, exploring the positive regulatory effects of risperidone. Methods: Ten pregnant Wistar rats were randomly divided into two groups on gestational day 9: one was injected with poly(I:C) to establish SCH model, and the other received saline. Nine male offspring were selected and randomly assigned to three groups (n=3):Normal(from saline grop), SCH, and SCH+Risperidone (Treated) group (from poly(I:C)). From 76 days of age, the Treated group was administered risperidone solution by gastric lavage, whereas the other two groups received distilled water, for a 28-day period. Thereafter, multimodal MRI scans were conducted: Structural MRI (sMRI) for bilateral hippocampal volume; diffusion tensor imaging (DTI) for hippocampal FA and ADC values; and magnetic resonance spectroscopy (MRS) for metabolite-to-creatine ratios: N-acetylaspartate to creatine (NAA/Cr), choline to creatine (Cho/Cr), glutamate to creatine (Glu/Cr), myo-inositol to creatine (mI/Cr). Results: Hippocampus Volume: Compared to the normal group, the SCH group exhibited a significant reduction in bilateral hippocampus volume ( Conclusions: The Poly(I:C)-induced schizophrenia rat model exhibits reduced hippocampal volume, neuronal damage, impaired white matter integrity, and glutamatergic system dysfunction. These preliminary findings suggest a potential modulatory effect of risperidone, warranting validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.